Skip to main content
. 2020 Jul 22;9:e55415. doi: 10.7554/eLife.55415

Figure 11. AGK2 treatment increases the efficacy of anti-TB drug INH.

Figure 11.

(A) Experimental plan for infection in BALB/c mice. (B–D) CFU enumeration to determine the bacterial burden in the lungs, spleen and liver of infected mice. (E) Schematic representation of the adjunct therapy experiment. A group of mice were infected with low dose of H37Rv. Following a rest of 15 days, mice were either left untreated or were treated with AGK2, INH or both. After 15 days of treatment, mice were euthanized for CFU enumeration in the lungs. (F) CFU from the lung homogenates of respective animals. (G) Schematic representation of the AGK2 treatment infection model. (H and I) CFU obtained from the lung homogenates of mice infected with MDR and XDR strains of Mtb with and without AGK2 treatment. The experiment was performed once with five mice in each group. Data is represented as mean ± SD (n = 5). *p<0.05, **p<0.005, ***p<0.0005.

Figure 11—source data 1. Efficacy of AGK2 as an adjunct to current anti-TB drug INH.
Source data for Figure 11B–D, F, H and I.